AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00849095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide/formoterol combination
Description: budesonide/formoterol 160/4.5 mcg 1 inhalation bid
Study NCT00849095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: bid inhaled placebo
Study NCT00849095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terbutaline
Description: as needed terbutaline 500 mcg for a period of 52 weeks
Study NCT00800254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: NMES 20 minutes twice a day for 6 weeks plus standard physical therapy
Study NCT00800254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation Protocol
Description: Standard physical therapy for 8 weeks after surgery
Study NCT02172417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine + Tiotropium
Study NCT02172417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine + Tiotropium
Study NCT02172417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Study NCT01771341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAQUET SERVOi ventilator with Edi Catheter
Description: NAVA respiratory modality
Study NCT01771341 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MAQUET SERVOi ventilator
Description: Pressure Support
Study NCT02408159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varicella Zoster Vaccine
Study NCT02408159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03790033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ucha-Shinki-Hwan
Description: Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g Achyranthes Root 1.0g Cornus Fruit 1.0g Dioscorea Rhizome 1.0g Psyllium Husk 1.0g Alisma Rhizome 1.0g Hoelen 1.0g Moutan Root Bark 1.0g Cinnamon Bark 0.3g Pulvis Aconiti Tuberis Purificatum 0.3g
Study NCT03790033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo granule
Study NCT04586842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based Occupational Therapy
Description: Domiciliary and Community-based Occupational Therapy on mental health and ABI intervention, developed on the basis of the Model Of Human Occupation.
Study NCT04586842 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard community-based intervention
Description: Interventions received at the community, public or private level (e.g. community nursing, social education and/or psychology).
Study NCT01454817 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life
Description: Improving Quality of Life
Study NCT01836978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program and stress reduction strategies.
Study NCT02427464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engensis (VM202)
Description: gene therapy
Study NCT02427464 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04476004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scapular-focused exercise
Description: scapular-focused exercise
Study NCT04476004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular-focused exercise
Description: scapular-focused exercise
Study NCT04476004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual feedback
Description: EMG visual feedback
Study NCT02106819 — intervention group
Intervention type: BEHAVIORAL
Intervention: Testing of emotional communication ability
Description: Assessment of comprehension and expression of emotional facial and prosodic expressions and assessment of emotional reactivity via ratings of emotionally evocative pictures and words.
Study NCT02106819 — intervention group
Intervention type: PROCEDURE
Intervention: magnetic resonance imaging (MRI) of the brain
Description: Cerebellar participants who score at least 1 and a 1/2 standard deviations below the mean on the Florida Affect Battery and who have no contra-indications to scanning will be given an MRI. Healthy control participants who are willing and able to be scanned will also be given an MRI of the brain to use for analysis comparison.
Study NCT01548833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delefilcon A contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear.
Study NCT01548833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear.
Study NCT01548833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narafilcon A contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear.
Study NCT01548833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narafilcon A contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear.
Study NCT01548833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filcon II 3 contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear
Study NCT01548833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filcon II 3 contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear
Study NCT04508088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronal T1 weighted spin echo images
Description: Coronal T1 weighted spin echo images will be obtained through the knee with a field of view of 16cm to include distal femoral and proximal tibial metaphyses.
Study NCT04508088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spin-lattice relaxation (T1)
Description: Spin-lattice relaxation (T1) relaxometry acquisition consisting of seven fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
Study NCT04508088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance spectroscopy
Description: Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at echo times of 20, 30, 40, and 50 ms using 32 signal averages per echo time with a TR of 2.5 s (total scan time = 5.4 minutes). Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
Study NCT04508088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and to perform immune studies. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). We will also evaluate molecular gene signatures from the blood samples that correlate with the previously described bone imaging phenotypes. At that point, the information will be used to develop a CyTOF panel to evaluate differences in immune cellular populations between CD patients with normal versus low BMD, and matched controls.
Study NCT03288142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertension Coaching Application and Home Monitor
Description: The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD
Study NCT03288142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Tracking Application and Home Monitor
Description: Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
Study NCT03170180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: sunitinib 37.5mg daily
Study NCT03170180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg daily
Study NCT03170180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400mg daily
Study NCT02046759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist- Intervention
Description: Patients received additional education on basic facts about asthma, role of medications, the difference between long-term control medications and quick-relief medications, as well as patient skills in the first visit then reinforcement every two weeks.. The importance of proper inhaler technique, avoidance of asthma triggers and self-monitoring of asthma were also highlighted. Visual aids, physical demonstration as well as written information resources were supplied. Asthma care plans were tailored to patient needs and preferences. Patients were informed how to detect early signs of worsening asthma, when and how to seek medical care as appropriate.
Study NCT02046759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Patients received usual care delivered by physician without pharmacist intervention. Patients were prescribed asthma medication with summarized basic information on asthma and medication use. Follow-up visits were not planned on consistent basis, but rather individually according to the disease status. No asthma action plans were provided.
Study NCT03903315 — intervention group
Intervention type: OTHER
Intervention: Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment
Description: Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment with reference to mortality and complications.
Study NCT01859520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: swim-up, density gradient sperm preparation techniques
Description: Sperms are prepared by sperm washing techniques before used in assisted reproductive technologies. Most commonly used sperm preparation methods are the swim up and the density gradient. Recent studies shows that the DNA integrity status of the spermatozoa is related to the success in assisted reproduction techniques. Sperm preparation methods may theoretically cause damage sperm DNA. Therefore it is important to select the optimum method of sperm preparation causing least sperm DNA damage. Aim of our study is to investigate and compare the effect two different sperm preparation techniques on DNA fragmentation.
Study NCT02879006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese Herbal Medication
Description: Capsules, 26 month course, starting 2 months pre-OIT
Study NCT02879006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT
Study NCT02879006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: 4 months course, starting 2 months pre-OIT through the 2 month build-up phase
Study NCT02879006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omalizumab
Description: 4 months course, starting 2 months pre-OIT through the 2 month build-up phase
Study NCT02879006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi OIT
Description: 24 months of multi OIT (maintenance dose of 1gm each food allergen)
Study NCT02879006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multi OIT
Description: 24 months of multi OIT (maintenance dose of 1gm each food allergen)
Study NCT00715910 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nimenrix
Description: One dose, as intramuscular injection
Study NCT00715910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: One dose, as intramuscular injection
Study NCT00715910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).
Study NCT00715910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).
Study NCT01700387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: onabotulinumtoxinA
Description: All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.
Study NCT01700387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.
Study NCT01700387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Subjects randomized to the onabotulinumtoxinA + topiramate group will receive:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period.
Study NCT01700387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the onabotulinumtoxinA + placebo group will receive:~Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period.
Study NCT02974699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potato Starch (Bob's Red Mill)
Description: Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.
Study NCT02974699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pregelatinized Starch (Resource ThickenUp)
Description: Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.
Study NCT04052256 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary computed tomography angiography
Description: Computational fluid dynamic model information derived from CT
Study NCT02481453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Experimental: rapamycin oral solution, 2 mg/day during one year Comparator: placebo
Study NCT02481453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator: placebo
Study NCT04424953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath videolaryngoscope
Description: A brand of a commonly-used videolaryngoscope which has a camera at the end of the laryngoscope to visualize the vocal cords
Study NCT04424953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope
Description: Classic direct laryngoscope that depends on visualization of the vocal cords by the operator
Study NCT04052178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS active and sham
Description: Repetitive transcranial magnetic stimulation of the pharyngeal sensory cortex.
Study NCT04052178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PES active and sham
Description: Intrapharyngeal electrical stimulation with a catheter delivering electrical pulses.
Study NCT04052178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin active and placebo
Description: Capsaicin solution (TRPV1 agonist) at a concentration of 10-5M or placebo solution.
Study NCT03904056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ISQ-RP
Description: Patients were treated with single-spot targeted retinal photocoagulation directed toward areas of retinal nonperfusion detected by fluorescein angiography. In this group, laser treatment was performed in two sessions (week 0 and 2), with a shot duration of 100 ms, but spots were placed 1/2 burn apart and power modulated in order to generate moderately white spots on the retina.~Retinal photocoagulation was performed with single-spot full-scatter PRP using Purepoint green diode laser (Alcon, Fortworth, Texas) with an Ocular Mainster PRP 165 lens with a dynamic field of view of 180 degrees, and a 200 micron spot size (which produces a 392 micron spot size on the retina). Intravitreal injection of 0.5 mg (0.05 ml) ranibizumab (Lucentis®) (IVR) were performed 180 minutes after the first laser session (week 0) by a single retina specialist.
Study NCT03904056 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ETDRS-PRP group
Description: Panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab
Study NCT00835562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical management
Description: Non-surgical management (physiotherapy and self-training)
Study NCT00835562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Description: Osteosynthesis with angle-stable plate followed by physiotherapy and self-training
Study NCT00835562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Description: Primary modular hemiarthroplasty followed by physiotherapy and self-training
Study NCT01467219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphadenectomy
Description: bilateral pelvic and para-aortic lymph node dissection
Study NCT01467219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional therapy
Description: hysterectomy, bilateral salpingo-oophorectomy,bilateral pelvic and para-aortic lymph node dissection +/- omentectomy via laparotomy, laparoscopy or robotic-assisted
Study NCT01467219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/ Computed Tomography
Description: Pre-operative PET/CT scan
Study NCT01467219 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: 5 MBq/kg body weight of FDG (up to 550 MBq)
Study NCT01690676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin
Study NCT01690676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Study NCT02323100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ravicti low dose
Description: 8 am, 4pm and midnight
Study NCT02323100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ravicti high dose
Description: 8 am, 4pm and midnight
Study NCT02323100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 am, 4pm and midnight
Study NCT03412565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.
Study NCT03412565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered as 1.3 mg/m\^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.
Study NCT03412565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.
Study NCT03412565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.